MaxCyte Analyst Ratings
BenzingaApr 23 11:21 ET
MaxCyte Analyst Ratings
BenzingaMar 13 08:01 ET
Analysts Offer Insights on Healthcare Companies: MaxCyte (GB:MXCT), Kura Oncology (KURA) and InMode (INMD)
TipRanksJan 23 04:09 ET
Craig-Hallum Initiates Coverage On MaxCyte With Buy Rating, Announces Price Target of $7
BenzingaNov 29, 2023 11:10 ET
MaxCyte Analyst Ratings
BenzingaNov 29, 2023 11:08 ET
Stephens & Co. Reiterates Overweight on MaxCyte, Maintains $12 Price Target
BenzingaOct 5, 2023 08:30 ET
MaxCyte Analyst Ratings
BenzingaOct 5, 2023 08:28 ET
Stephens & Co. Reiterates Overweight on MaxCyte, Maintains $12 Price Target
BenzingaMar 28, 2023 07:26 ET
MaxCyte analyst ratings
Benzinga Analyst RatingsAug 15, 2022 07:04 ET
BTIG Maintains Buy on MaxCyte, Raises Price Target to $11
Benzinga Real-time NewsAug 15, 2022 07:04 ET
No Data
No Data